153 related articles for article (PubMed ID: 29028590)
1. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials.
Giacobbe P; Rakita U; Lam R; Milev R; Kennedy SH; McIntyre RS
J Affect Disord; 2018 Jan; 226():294-300. PubMed ID: 29028590
[TBL] [Abstract][Full Text] [Related]
2. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
3. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.
Madhoo M; Keefe RS; Roth RM; Sambunaris A; Wu J; Trivedi MH; Anderson CS; Lasser R
Neuropsychopharmacology; 2014 May; 39(6):1388-98. PubMed ID: 24309905
[TBL] [Abstract][Full Text] [Related]
4. A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.
Richards C; Iosifescu DV; Mago R; Sarkis E; Geibel B; Dauphin M; McIntyre RS; Weisler R; Brawman-Mintzer O; Gu J; Madhoo M
J Clin Psychopharmacol; 2018 Aug; 38(4):336-343. PubMed ID: 29912786
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.
Richards C; Iosifescu DV; Mago R; Sarkis E; Reynolds J; Geibel B; Dauphin M
J Psychopharmacol; 2017 Sep; 31(9):1190-1203. PubMed ID: 28857719
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.
Maneeton B; Maneeton N; Likhitsathian S; Suttajit S; Narkpongphun A; Srisurapanont M; Woottiluk P
Drug Des Devel Ther; 2015; 9():1927-36. PubMed ID: 25897203
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
[TBL] [Abstract][Full Text] [Related]
11. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
[TBL] [Abstract][Full Text] [Related]
14. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
15. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
[TBL] [Abstract][Full Text] [Related]
16. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
Kornstein SG; Bliss C; Kando J; Madhoo M
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
[TBL] [Abstract][Full Text] [Related]
18. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]